Askgene Limited Announces Completion Of Usd 20 Million Series A Financing Led By Qiming Venture Partners And Tf Capital

May 09, 2022•about 3 years ago

Amount Raised

$20 Million

Round Type

series a

Camarillo

Description

AskGene Limited ("AskGene"), a clinical-stage biopharmaceutical company focusing on discovery and development of innovative biological drugs, today announced the completion of USD 20 million in Series A financing. The financing was led by Qiming Venture Partners and TF Capital. Proceeds from the financing will be used to advance clinical development of AskGene's robust pipeline of innovative therapeutic candidates and development of SmartKine® cytokine prodrug platform.

Company Information

Company

Ask Gene

Location

Camarillo, California, United States

About

AskGene is an innovative company advancing immunotherapies for cancers and autoimmune diseases. The vision of the company is to apply next-generation platform technology to unlock the full therapeutic potential of cytokines with better safety profiles. Through its SmartKine® platform technology and pipeline programs, AskGene aspires to achieve its overarching objective of modulating immune system at a disease site with selectivity and precision. Additional clinical stage programs include ASKB589 (an anti-CLDN 18.2 antibody in phase I/II) and ASKG712 (an anti-VEGF antibody-ANG2 antagonist peptide fusion molecule in phase I). SOURCE AskGene Limited

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Askgene Limited Announces Completion Of Usd 20 Million Series A Financing Led By Qiming Venture Partners And Tf Capital

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information